Regulatory flexibility can make continuous improvement possible.
Mark Rosolowsky
Advertisement
Mark Rosolowsky is the executive director of global regulatory sciencesâCMC at Bristol Myers Squibb
Articles by Mark Rosolowsky
Second in a three-part series that discusses the complexities of QbD implementation in biotech development.
First in a three-part series that discusses the complexities of QbD implementation in biotech product development.
Advertisement
Latest Updated Articles
Quality by Design for Biotechnology Products—Part 3January 1st 2010
Quality by Design for Biotechnology Products—Part 2December 1st 2009
Quality by Design for Biotechnology Products—Part 1November 1st 2009
Advertisement
Advertisement
Trending on BioPharm International
1
Sanofi Begins Construction of EU-Backed Insulin Plant in Frankfurt
2
Zylidac Bio to Scale Prolific's Optogenetic Cell Line Platform to GMP
3
TaiMed’s Anti-CD4 Antibody TMB-365 Reduces HIV Viral Load in Phase 1, Supporting Long-Acting Combination Regimens
4
Akeso's Ivonescimab Enters Phase 2/3 Biliary Tract Cancer Trial in US
5